Display options
Cite
Mutiso JM, Macharia JC, Taracha E, et al. Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). J Biomed Res. 2012;26(1):8-16doi: 10.1016/S1674-8301(12)60002-5.
Mutiso, J. M., Macharia, J. C., Taracha, E., & Gicheru, M. M. (2012). Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). Journal of biomedical research, 26(1), 8-16. https://doi.org/10.1016/S1674-8301(12)60002-5
Mutiso, Joshua Muli, et al. "Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)." Journal of biomedical research vol. 26,1 (2012): 8-16. doi: https://doi.org/10.1016/S1674-8301(12)60002-5
Mutiso JM, Macharia JC, Taracha E, Gicheru MM. Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). J Biomed Res. 2012 Jan;26(1):8-16. doi: 10.1016/S1674-8301(12)60002-5. PMID: 23554725; PMCID: PMC3596075.
Copy Download .nbib Format: NLM
Share it on

J Biomed Res. 2012 Jan;26(1):8-16. doi: 10.1016/S1674-8301(12)60002-5.

Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Journal of biomedical research

Joshua Muli Mutiso, John Chege Macharia, Evans Taracha, Michael Muita Gicheru

Affiliations

  1. Department of Tropical and Infectious Diseases, Institute of Primate Research, Karen, Nairobi 24481-00502, Kenya; ; Department of Zoological Sciences, Kenyatta University, Nairobi 43844-00100, Kenya.

PMID: 23554725 PMCID: PMC3596075 DOI: 10.1016/S1674-8301(12)60002-5

Abstract

In a previous immunogenicity and efficacy study in mice, montanide ISA 720 (MISA) was indicated to be a better adjuvant than bacillus calmette guerin vaccine (BCG) for a Leishmania vaccine. In the present study, we report the safety, immunogenicity and efficacy of Leishmania donovani (L. donovani) sonicated antigen delivered with alum-BCG (AlBCG), MISA or monophosphoryl lipid A (MPLA) in vervet monkeys following intradermal inoculums. Vaccinated and control animals were challenged with virulent L. donovani parasites and the parasitic burden was determined. Only animals vaccinated with alum-BCG adversely reacted to the inoculum by producing ulcerative erythematous skin indurations. Non-parametric ANOVA followed by a post test showed significantly higher IgG antibodies, and revealed the presence of lymphoproliferative and interferon gamma responses in both AlBCG+Ag and MISA+Ag as compared to the MPLA+Ag or other groups (P < 0.001). We conclude that L. donovani sonicated antigen containing MISA is safe and is associated with protective immune response against Leishmania donovani infection in the vervet monkey model.

Keywords: Leishmania donovani; adjuvants; sonicated antigen; vervet monkey; visceral leishmaniasis

References

  1. Hum Vaccin. 2011 Jan-Feb;7 Suppl:10-5 - PubMed
  2. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7914-9 - PubMed
  3. Clin Immunol. 2005 Nov;117(2):182-91 - PubMed
  4. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):58-63 - PubMed
  5. Scand J Immunol Suppl. 1992;11:48-52 - PubMed
  6. Infect Immun. 1997 Sep;65(9):3520-8 - PubMed
  7. Mem Inst Oswaldo Cruz. 1999 Jul-Aug;94(4):491-6 - PubMed
  8. Vaccine. 2001 May 14;19(25-26):3485-92 - PubMed
  9. J Immunol. 2007 Sep 1;179(5):3161-70 - PubMed
  10. FEMS Immunol Med Microbiol. 2007 Nov;51(2):229-42 - PubMed
  11. Indian J Med Res. 2006 Mar;123(3):423-38 - PubMed
  12. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10267-71 - PubMed
  13. Clin Exp Immunol. 2005 May;140(2):349-53 - PubMed
  14. Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):365-8 - PubMed
  15. Vaccine. 2005 May 25;23(28):3642-8 - PubMed
  16. Scand J Immunol. 1995 Feb;41(2):202-8 - PubMed
  17. Vaccine. 1999 May 4;17(18):2311-9 - PubMed
  18. Infect Immun. 2008 Mar;76(3):1003-15 - PubMed
  19. Vaccine. 2009 Jul 30;27(35):4747-53 - PubMed
  20. Trop Biomed. 2010 Apr;27(1):89-102 - PubMed
  21. Vaccine. 2009 Dec 10;28(1):53-62 - PubMed
  22. Med Parazitol (Mosk). 1999 Jan-Mar;(1):58-9 - PubMed
  23. Indian J Med Res. 2006 Mar;123(3):245-66 - PubMed
  24. J Glob Infect Dis. 2010 May;2(2):135-46 - PubMed
  25. Vaccine. 2010 Mar 2;28(10):2236-2242 - PubMed
  26. Br Med Bull. 2006 Jul 17;75-76:115-30 - PubMed
  27. Trans R Soc Trop Med Hyg. 1982;76(6):741-6 - PubMed
  28. Indian J Med Res. 2006 Mar;123(3):439-54 - PubMed
  29. Microb Pathog. 2005 Apr;38(4):147-60 - PubMed
  30. Parasite Immunol. 1993 Feb;15(2):75-84 - PubMed
  31. J Infect Dis. 2003 Oct 15;188(8):1250-7 - PubMed
  32. Vaccine. 2002 Nov 1;20(31-32):3658-67 - PubMed
  33. Cell Immunol. 1985 Aug;94(1):11-20 - PubMed
  34. Infect Immun. 2005 Jun;73(6):3587-97 - PubMed
  35. Regul Toxicol Pharmacol. 2002 Jun;35(3):398-413 - PubMed
  36. Infect Immun. 1993 Dec;61(12):5205-13 - PubMed
  37. Infect Immun. 1997 Jun;65(6):2371-7 - PubMed
  38. Infect Immun. 2001 Jan;69(1):245-51 - PubMed
  39. Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):123-6 - PubMed
  40. Braz J Med Biol Res. 2005 Jul;38(7):979-84 - PubMed
  41. Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S58-61 - PubMed
  42. J Immunol. 1999 Oct 15;163(8):4481-8 - PubMed
  43. Ann Trop Med Parasitol. 1995 Dec;89 Suppl 1:83-8 - PubMed
  44. Parasite Immunol. 2009 Sep;31(9):520-8 - PubMed
  45. Acta Trop. 2011 Jul;119(1):50-6 - PubMed
  46. Exp Parasitol. 1997 Feb;85(2):109-16 - PubMed
  47. Rev Inst Med Trop Sao Paulo. 2010 Mar-Apr;52(2):95-100 - PubMed
  48. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):12-20 - PubMed
  49. Vaccine. 2001 Jul 20;19(30):4328-36 - PubMed
  50. Rev Inst Med Trop Sao Paulo. 2011 May-Jun;53(3):129-32 - PubMed
  51. Infect Immun. 2007 Sep;75(9):4648-54 - PubMed
  52. Expert Rev Vaccines. 2003 Apr;2(2):239-52 - PubMed
  53. J Biomed Res. 2010 Jan;24(1):16-25 - PubMed

Publication Types